Kevin Kim

Trials

Studies that name Kevin Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:10 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03925350 · Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

  California Pacific Medical Center Research Institute · unknown · Metastatic Melanoma · principal investigator
• Ph2
  NCT01851408 · Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

  National Cancer Institute (NCI) · withdrawn · Melanoma, Recurrent Melanoma, Stage III Melanoma · principal investigator
• Ph1
  NCT01434459 · Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

  Emory University · terminated · Pancreatic Neoplasms, Cholangiocarcinoma · principal investigator
• Ph1
  NCT00600496 · A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

  AstraZeneca · completed · Breast Cancer, Breast Neoplasms, Colon Cancer · principal investigator
• Ph1
  NCT00349206 · Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

  National Cancer Institute (NCI) · completed · Melanoma, Recurrent Melanoma, Stage III Melanoma · principal investigator
• Ph2
  NCT00082875 · Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

  National Cancer Institute (NCI) · terminated · Stage III Melanoma, Stage IV Melanoma · principal investigator
• Ph2
  NCT00027586 · Imatinib Mesylate in Treating Patients With Metastatic Melanoma

  M.D. Anderson Cancer Center · completed · Melanoma, Skin Neoplasms · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-11 21:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 16 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Beta 1 Integrins and Cellular Responses to TGFbeta
  F32GM075419 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2005 · $55,352 awarded in 2005
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
  Named on NCT00349206, NCT00027586